232 related articles for article (PubMed ID: 16127052)
41. Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses.
Tan H; Derrick J; Hong J; Sanda C; Grosse WM; Edenberg HJ; Taylor M; Seiwert S; Blatt LM
J Interferon Cytokine Res; 2005 Oct; 25(10):632-49. PubMed ID: 16241862
[TBL] [Abstract][Full Text] [Related]
42. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection.
Suzuki F; Arase Y; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Takagi K; Satoh J; Kumada H
J Viral Hepat; 2004 May; 11(3):271-6. PubMed ID: 15117331
[TBL] [Abstract][Full Text] [Related]
43. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
[TBL] [Abstract][Full Text] [Related]
44. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA.
Vlotides G; Sörensen AS; Kopp F; Zitzmann K; Cengic N; Brand S; Zachoval R; Auernhammer CJ
Biochem Biophys Res Commun; 2004 Jul; 320(3):1007-14. PubMed ID: 15240148
[TBL] [Abstract][Full Text] [Related]
45. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene.
Lallemand C; Meritet JF; Erickson R; Grossberg SE; Roullet E; Lyon-Caen O; Lebon P; Tovey MG
J Interferon Cytokine Res; 2008 Jun; 28(6):393-404. PubMed ID: 18593334
[TBL] [Abstract][Full Text] [Related]
46. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
47. Endogenous IFNγ in chronic HCV genotype 4 patients treated with PEG-IFNα and ribavirin.
Sadeq R; Mohtady H; Al Badawy N; Ibrahim S; Omar AR; Husseiny MI; El Zowalaty M
J Infect Dev Ctries; 2013 Nov; 7(11):859-67. PubMed ID: 24240045
[TBL] [Abstract][Full Text] [Related]
48. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.
Buckwold VE; Wei J; Huang Z; Huang C; Nalca A; Wells J; Russell J; Collins B; Ptak R; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
Antiviral Res; 2007 Feb; 73(2):118-25. PubMed ID: 16987555
[TBL] [Abstract][Full Text] [Related]
49. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.
Kamal SM; Ismail A; Graham CS; He Q; Rasenack JW; Peters T; Tawil AA; Fehr JJ; Khalifa Kel S; Madwar MM; Koziel MJ
Hepatology; 2004 Jun; 39(6):1721-31. PubMed ID: 15185314
[TBL] [Abstract][Full Text] [Related]
50. Biological characterisation of a recombinant Atlantic salmon type I interferon synthesized in Escherichia coli.
Ooi EL; Verjan N; Hirono I; Nochi T; Kondo H; Aoki T; Kiyono H; Yuki Y
Fish Shellfish Immunol; 2008 May; 24(5):506-13. PubMed ID: 18329900
[TBL] [Abstract][Full Text] [Related]
51. [Progress of the study on the relationship between MxA and interferon therapy of viral hepatitis].
Du T; Liu Y
Zhonghua Gan Zang Bing Za Zhi; 2005 Dec; 13(12):957-9. PubMed ID: 16381656
[No Abstract] [Full Text] [Related]
52. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
[TBL] [Abstract][Full Text] [Related]
53. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
[TBL] [Abstract][Full Text] [Related]
54. [Comparison of hepatitis C viral RNA and core antigen kinetics in the therapeutic follow up of hepatitis C virus and human immunodeficiency virus co-infected patients, treated by bitherapy interferon-ribavirin, within the framework of RIBAVIC protocol].
Pivert A; Payan C; Lunel F;
Pathol Biol (Paris); 2004 Nov; 52(9):522-8. PubMed ID: 15531116
[TBL] [Abstract][Full Text] [Related]
55. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.
Toniutto P; Fabris C; Fumo E; Apollonio L; Caldato M; Avellini C; Minisini R; Pirisi M
J Gastroenterol Hepatol; 2005 Apr; 20(4):577-82. PubMed ID: 15836706
[TBL] [Abstract][Full Text] [Related]
56. Regulation of IFN-alpha/beta, MxA, 2',5'-oligoadenylate synthetase, and HLA gene expression in influenza A-infected human lung epithelial cells.
Ronni T; Matikainen S; Sareneva T; Melén K; Pirhonen J; Keskinen P; Julkunen I
J Immunol; 1997 Mar; 158(5):2363-74. PubMed ID: 9036986
[TBL] [Abstract][Full Text] [Related]
57. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells.
Buckwold VE; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):62-70. PubMed ID: 16867173
[TBL] [Abstract][Full Text] [Related]
58. A recombinant CHSE-214 cell line expressing an Mx1 promoter-reporter system responds to both interferon type I and type II from salmonids and represents a versatile tool to study the IFN-system in teleost fish.
Jørgensen JB; Johansen A; Hegseth MN; Zou J; Robertsen B; Collet B; Secombes CJ
Fish Shellfish Immunol; 2007 Dec; 23(6):1294-303. PubMed ID: 17804253
[TBL] [Abstract][Full Text] [Related]
59. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
60. Emergence and decay of the human Mx homolog in cancer patients during and after interferon-alpha therapy.
Jakschies D; Hochkeppel H; Horisberger M; Deicher H; von Wussow P
J Biol Response Mod; 1990 Jun; 9(3):305-12. PubMed ID: 2380745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
